Circulating Resistin Levels and Risk of Colorectal Cancer: A Meta-Analysis

Table 1

Characteristics of the studies included in meta-analysis.

References	Country	Blood sample	Study design	Case/control, number	Assay method and resource	Assay resource	Total resistin means (ng/mL) and SD
Kumor et al. 2009 [24]	Poland	Serum	Case-control	36/25	ELISA	R&D Systems	6.79 ± 2.41/3.6 ± 1.08
Gonullu et al. 2010 [26]	Turkey	Serum	Case-control	36/37	ELISA	BioSource	6.1 ± 3.3/4.5 ± 1.5
Nakajima et al. 2010 [23]	Japan	Plasma	Case-control	115/115	ELISA	BioVender Laboratory Medicine	4.5 (3.1–6.4)/3.1 (2.2–4.7)
Danese et al. 2012 [27]	Italy	Serum	Case-control	40/40	ELISA	Mediagnost	5.88 (1.84–22.35)/4.94 (1.82–8.16)
Hillenbrand et al. 2012 [32]	Germany	Plasma	Case-control	67/60	Multiplex immunoassay	Millipore	10.9 (4.2–43.5)/10.8 (5.2–24.9)
Ho et al. 2012 [31]	USA	Plasma	Case-cohort	456/834	Multiplex immunoassay	Millipore	12.8 (9.9–16.4)/12.3 (9.8–15.6)
Joshi et al. 2014 [18]	South Korea	Serum	Case-control	100/100	ELISA kit	Adipogen	4.9 ± 2.3/2.8 ± 1.7
Lu et al. 2010 [28]	China	Serum	Case-control	30/30	ELISA	ADL	7.72 ± 2.6/7.42 ± 3.72
Tulubas et al. 2014 [21]	Turkey	Serum	Case-control	30/30	ELISA	AssayMax ELISA kit	18.77 ± 5.09/13.36 ± 6.36
Wägsäter et al. 2008 [29]	Sweden	Plasma	Case-control	35/34	ELISA	R&D Systems	3.95 (1.50–2.40)/5.25 (2.00–3.00)
Kosova et al. 2013 [25]	Turkey	Serum	Case-control	20/20	ELISA	Millipore Corporation	4.92 ± 2.2/3.39 ± 1.1

Median (interquartile range).
Media (range).